0001209191-15-059676.txt : 20150706 0001209191-15-059676.hdr.sgml : 20150703 20150706175958 ACCESSION NUMBER: 0001209191-15-059676 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150701 FILED AS OF DATE: 20150706 DATE AS OF CHANGE: 20150706 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALDER BIOPHARMACEUTICALS INC CENTRAL INDEX KEY: 0001423824 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11804 NORTH CREEK PARKWAY SOUTH CITY: BOTHELL STATE: WA ZIP: 98011 BUSINESS PHONE: 425-205-2900 MAIL ADDRESS: STREET 1: 11804 NORTH CREEK PARKWAY SOUTH CITY: BOTHELL STATE: WA ZIP: 98011 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Litton Mark James CENTRAL INDEX KEY: 0001604834 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36431 FILM NUMBER: 15974537 MAIL ADDRESS: STREET 1: 11804 NORTH CREEK PARKWAY SOUTH CITY: BOTHELL STATE: WA ZIP: 98011 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-07-01 0 0001423824 ALDER BIOPHARMACEUTICALS INC ALDR 0001604834 Litton Mark James 11804 NORTH CREEK PARKWAY SOUTH BOTHELL WA 98011 0 1 0 0 Chief Business Officer Common Stock 2015-07-01 4 S 0 7500 51.0959 D 67655 D Common Stock 30000 I Held in trust for the benefit of Reporting Person's minor child Common Stock 30000 I Held in trust for the benefit of Reporting Person's minor child Common Stock 30000 I Held in trust for the benefit of Reporting Person's minor child The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2014. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.04 to $54.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4. /s/ Mark J. Litton 2015-07-06